For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

JEVTANA Patients Received a Median of 6 or 7 Treatment Cycles in the PROSELICA Trial1

Treatment Duration by Study Arm Regardless of Dose Reductions1

JEVTANA 20 mg/m2 + prednisone (n=580)
JEVTANA 25 mg/m2 + prednisone (n=595)
0 1 2 3 4 5 6 7

Median Number of Cycles

  • In the 25 mg/m2 group, 128 patients (22%) had a dose reduced from 25 to 20 mg/m2, 19 patients (3%) had a dose reduced from 20 to 15 mg/m2 and 1 patient (0.2%) had a dose reduced from 15 to 12 mg/m2.
  • In the 20 mg/m2 group, 58 patients (10%) had a dose reduced from 20 to 15 mg/m2, and 9 patients (2%) had a dose reduced from 15 to 12 mg/m2.
In TROPIC, patients treated with JEVTANA 25 mg/m2 received a median of 6 treatment cycles, with 29.4% of patients (109 out of 371) completing the maximum of 10 treatment cycles.2
  • TROPIC was limited to a maximum of 10 treatment cycles to minimize risk of mitoxantrone-induced cardiac toxicity.3



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.